Search results for "Prognosis."

showing 10 items of 2044 documents

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyendocrine system diseases[SDV.CAN]Life Sciences [q-bio]/Cancermedicine.disease_causeNSCLClcsh:RC254-28203 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerNon-small cell lung cancerInternal medicinemedicineOverall survivalNon–small cell lung cancerStage (cooking)neoplasms030304 developmental biology0303 health sciencesMutationTransition (genetics)business.industryKRAS mutationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisConfidence intervaldigestive system diseases3. Good healthrespiratory tract diseasesOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleKRASbusinessKras mutation
researchProduct

Clinical implications of airway hyper-responsiveness in COPD

2006

COPD represents one of the leading causes of mortality in the general population. This study aimed at evaluating the relationship between airway hyperresponsiveness (AHR) and COPD and its relevance for clinical practice. We performed a MEDLINE search that yielded a total of 1919 articles. Eligible studies were defined as articles that addressed specific aspects of AHR in COPD, such as prevalence, pathogenesis, or prognosis. AHR appears to be present in at least one out of two individuals with COPD. The occurrence of AHR in COPD is influenced by multiple mechanisms, among which impairment of factors that oppose airway narrowing plays an important role. The main determinants of AHR are reduct…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtymedicine.medical_treatmentMEDLINEPopulationReviewsSettore MED/10 - Malattie Dell'Apparato RespiratorioBioinformaticsBronchial Provocation TestsPathogenesisDiagnosis DifferentialMedical Subject HeadingsPulmonary Disease Chronic ObstructivePredictive Value of TestsmedicineRespiratory HypersensitivityCOPDHumansairway smooth muscle aging bronchial obstructioneducationLungAsthmaCOPDeducation.field_of_studyLungbusiness.industryHealth Policyairway hyperresponsivenessSmokingPublic Health Environmental and Occupational HealthGeneral Medicinerespiratory systemmedicine.diseasePrognosisAsthmarespiratory tract diseasesbronchial hyperreactivitymedicine.anatomical_structurePredictive value of testsSmoking cessationbusinessAirwayInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Should atopy be assessed in elderly patients with respiratory symptoms suggestive of asthma?

2010

Aging is associated with modifications of the immune system and this could contribute to a reduced prevalence of allergic disease in the elderly. Atopy has rarely been considered in the clinical assessment of the geriatric respiratory patient. This article is a review of the available literature assessing the impact of age on atopy in the asthmatic patient. In the majority of papers, we found a lower prevalence of atopy in the most advanced ages, both in healthy subjects and in individuals affected by allergic respiratory diseases. No large, longitudinal studies performed in the general population have been conducted to confirm this observation. Although available data seem to favor the dec…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAgingPopulationDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Emedicine.disease_causeAtopyAllergic sensitizationAllergenmedicineHypersensitivityPrevalenceImmunology and AllergyHumansaging allergy asthmaRespiratory systemeducationAsthmaAgedAged 80 and overeducation.field_of_studybiologybusiness.industryPublic Health Environmental and Occupational HealthAge FactorsAllergensmedicine.diseasePrognosisAsthmaImmunologybiology.proteinbusinessExpert review of respiratory medicine
researchProduct

Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials.

2017

Defining a “higher-risk” population among intermediate-risk patients with pulmonary embolism included in PEITHO http://ow.ly/JM7u30hcSgN

Pulmonary and Respiratory MedicineResearch designAdultRiskmedicine.medical_specialtymedicine.medical_treatmentPopulationMEDLINEHemorrhageComorbidity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineText miningFibrinolytic AgentsmedicineHumansThrombolytic Therapy030212 general & internal medicineProspective StudiesIntensive care medicineeducationProspective cohort studyeducation.field_of_studybusiness.industryPatient SelectionAnticoagulantsThrombolysismedicine.diseasePrognosisComorbidityPulmonary embolismTreatment OutcomeEchocardiographyResearch DesignTenecteplasebusinessPulmonary EmbolismThe European respiratory journal
researchProduct

Alternative ways of expressing FEV1 and mortality in elderly people with and without COPD

2013

Expressing forced expiratory volume in 1 s (FEV1) as % predicted relies on the assumption of proportional variability and generalisability of prediction equations that may be unrealistic, especially for elderly people. We evaluated the prognostic implications of alternative ways of expressing FEV1. We enrolled 318 patients with chronic obstructive pulmonary disease (COPD) and 475 controls in the Salute Respiratoria nell'Anziano (SARA) study. The risk for 5-, 10- and 15-year mortality associated with FEV1 was studied by expressing FEV1 % pred, standardised by height cubed (FEV1 · Ht(-3)) and as a multiple of the sex-specific first percentile (FEV1 quotient (FEV1Q)). In the group with COPD, t…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.medical_specialtyPediatricsPercentilePrognosiPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioRate ratioPulmonary Disease Chronic ObstructiveElderly populationInternal medicineForced Expiratory VolumeHumansMedicineElderly peopleRespiratory Function TestAgedCOPDmedicine.diagnostic_testbusiness.industryRespiratory Function Tests; Spirometry; Humans; Treatment Outcome; Prognosis; Case-Control Studies; Aged; Middle Aged; Forced Expiratory Volume; Male; Female; Pulmonary Disease Chronic ObstructiveCase-control studyrespiratory systemMiddle AgedPrognosismedicine.diseaseRespiratory Function Testsrespiratory tract diseasesTreatment OutcomeSpirometryCase-Control StudiesFemalebusinessCase-Control StudieHuman
researchProduct

Exercise ECG Testing and Stress Cardiac Magnetic Resonance for Risk Prediction in Patients With Chronic Coronary Syndrome

2021

Vasodilator stress cardiac magnetic resonance (VS-CMR) has become crucial in the workup of patients with known or suspected chronic coronary syndrome (CCS). Whether traditional exercise ECG testing (ExECG) contributes prognostic information beyond VS-CMR is unclear.We retrospectively included 288 patients with known or suspected CCS who had undergone ExECG and subsequent VS-CMR in our institution. Clinical, ExECG, and VS-CMR variables were recorded. We defined the serious adverse events (SAE) as a combined endpoint of acute coronary syndrome, admission for heart failure, or all-cause death.During a mean follow-up of 4.2 ± 2.15 yr, we registered 27 SAE (15 admissions for acute coronary syndr…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAcute coronary syndromeMagnetic Resonance SpectroscopyVasodilator stressCoronary Artery DiseaseRisk AssessmentElectrocardiographyPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineExercise ecgIn patientAdverse effectRetrospective Studiesbusiness.industryRehabilitationPrognosismedicine.diseaseHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonancePerfusionJournal of Cardiopulmonary Rehabilitation and Prevention
researchProduct

Cardiovascular Events During and After Bronchiectasis Exacerbations and Long-term Mortality.

2022

ABSTRACT Background Population-based and retrospective studies have shown that risk for cardiovascular events such as arrythmias, ischemic episodes or heart failure, increase during and after bronchiectasis exacerbations. Research Question What are the risk factors for cardiovascular events (CVE) during and after bronchiectasis exacerbations and its impact on mortality? Study Design and Methods This was a post-hoc retrospective analysis of a prospective observational study of 250 patients with bronchiectasis at two tertiary care hospitals. Only the first exacerbation was considered for each patient, collecting demographic, comorbidity, and severity data. The main outcomes were the appearanc…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDeducation.field_of_studyBronchiectasisExacerbationbusiness.industryPopulationHazard ratioRetrospective cohort studyCritical Care and Intensive Care Medicinemedicine.diseasePrognosisComorbidityBronchiectasisCommunity-acquired pneumoniaCardiovascular DiseasesRisk FactorsInternal medicinemedicineHumansCardiology and Cardiovascular MedicinebusinesseducationRetrospective StudiesChest
researchProduct

Obstructive sleep apnea and comorbidities: a dangerous liaison

2018

Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with OSA are increasingly reported. A high comorbidity burden worsens prognosis, but some data suggest that CPAP might be protective especially in patients with comorbidities. Aim of this narrative review is to provide an update on recent studies, with special attention to cardiovascular and cerebrovascular comorbidities, the metabolic syndrome and type 2 diabetes, asthma, COPD and cancer. Better phenotypic characterization of OSA patients, including comorbi…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyDiseaseType 2 diabetesReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinecardiovascular diseaseDiabetes mellitusmedicinecancerCOPDMortalityIntensive care medicineAsthmalcsh:RC705-779COPDdiabetesbusiness.industrylcsh:Diseases of the respiratory systemasthmamedicine.diseaseComorbiditynervous system diseasesrespiratory tract diseasesObstructive sleep apnea030228 respiratory systemdiabeteprognosisMetabolic syndromebusiness030217 neurology & neurosurgeryMultidisciplinary Respiratory Medicine
researchProduct

German Thoracic Research Scholarship 1996: lung volume reduction for endstage pulmonary emphysema at the Washington University of St. Louis.

1998

The Thoracic Research Scholarship 1996 of the German Society for Thoracic and Cardiovascular Surgery enabled me to visit Barnes Hospital at the Washington University of St. Louis, USA, from May to July 1996. At that center Prof. J. D. Cooper has established lung-volume reduction surgery as a successful surgical treatment for patients with endstage pulmonary emphysema. The operation is performed using left-sided double-lumen intubation. After opening of the chest and pleura and starting single-lung ventilation the less diseased parts of the second lung collapse due to absorption atelectasis whereas the more diseased portion of the lung stays hyperinflated. Linear staplers buttressed with bov…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyUniversitiesmedicine.medical_treatmentPulmonary emphysemaAtelectasisGermanyPreoperative CaremedicineIntubationAnimalsHumansLung volumesLung Diseases ObstructiveFellowships and ScholarshipsPneumonectomySocieties MedicalLungMissouribusiness.industryPerioperativerespiratory systemLength of Staymedicine.diseasePrognosisrespiratory tract diseasesSurgerySt louismedicine.anatomical_structureTreatment OutcomePulmonary EmphysemaBreathingSurgeryCattleCardiology and Cardiovascular MedicinebusinessThe Thoracic and cardiovascular surgeon
researchProduct

Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?

2017

Pulmonary embolism (PE) is a major cause of both acute and long-term morbidity for a large number of patients worldwide, and massive PE is frequently fatal. Right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of PE. Patients with clinically overt RV failure, that is, with cardiogenic shock or persistent hypotension at presentation (acute high-risk PE), are clearly in need of immediate reperfusion treatment with systemic thrombolysis or, alternatively, surgical or catheter-directed techniques. On the other hand, within the large group of patients presenting without hemodynamic instability, the bleeding risk of full-dose intravenous thrombolytic treatment h…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemodynamicsSalvage therapy030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineFibrinolysismedicineHumansThrombolytic TherapyDecompensation030212 general & internal medicineWatchful WaitingIntensive care medicineSalvage Therapybusiness.industryCardiogenic shockAnticoagulantsThrombolysisPrognosismedicine.diseasePulmonary embolismAcute DiseaseCardiologyPulmonary EmbolismbusinessWatchful waitingSeminars in Respiratory and Critical Care Medicine
researchProduct